# First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy

> **NCT00389155** · PHASE2,PHASE3 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 34 (actual)

## Conditions studied

- Bladder Cancer
- Transitional Cell Carcinoma
- Metastasis

## Interventions

- **DRUG:** Vinflunine
- **DRUG:** Gemcitabine
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT00389155
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** 2008-01
- **Final completion:** 2008-01
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2015-12-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00389155

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00389155, "First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00389155. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*